Clinical bottom line
Circulating tumor DNA (ctDNA) analysis is an emerging tool with potential to guide treatment adaptation in metastatic bladder cancer, particularly muscle-invasive bladder cancer (MIBC). Early evidence suggests that ctDNA dynamics may help identify patients who benefit from immunotherapy or chemotherapy adjustments, enabling more personalized and timely treatment decisions. However, current data remain preliminary and largely hypothesis-generating, warranting prospective validation before routine clinical implementation.
What the evidence shows
Recent studies have explored ctDNA as a biomarker for treatment monitoring and adaptation in metastatic bladder cancer. Malshy Kamil et al. (2026) demonstrated that ctDNA-guided adjuvant immunotherapy in MIBC could identify patients with minimal residual disease who might benefit from early immunotherapy escalation, potentially improving outcomes. This study highlighted that ctDNA positivity after initial treatment correlated with higher relapse risk, supporting its role as a dynamic marker for treatment stratification.
Lindskrog Viborg et al. (2024) reviewed the evolving landscape of ctDNA-guided treatment in MIBC, emphasizing that serial ctDNA measurements can reflect tumor burden and treatment response more sensitively than conventional imaging. They discussed how ctDNA profiling may detect emerging resistance mutations, allowing for timely therapeutic switches. Anderson et al. (2026) further argued that ctDNA could redefine treatment paradigms in bladder cancer by enabling adaptive therapy approaches, although they cautioned that standardized assays and clinical validation are needed.
Additional data from related solid tumors, such as metastatic colorectal cancer, underscore the broader applicability of ctDNA-guided treatment adaptation (Case Medical Research et al., 2000; unnamed 2024 colorectal cancer study), providing a rationale for similar strategies in bladder cancer. However, bladder cancer-specific evidence remains limited, with most studies focusing on muscle-invasive disease rather than metastatic settings.
Caveats and uncertainty
Despite promising findings, several limitations temper enthusiasm for immediate clinical adoption. Most ctDNA studies in metastatic bladder cancer are small, single-center, or retrospective, limiting generalizability. Assay variability and lack of standardized thresholds for ctDNA positivity complicate interpretation and cross-study comparisons. The kinetics of ctDNA clearance or re-emergence during treatment are not yet fully characterized in bladder cancer, and the optimal timing and frequency of sampling remain undefined.
Furthermore, the impact of ctDNA-guided treatment changes on long-term survival and quality of life is unclear. Prospective randomized trials are needed to confirm that ctDNA-informed adaptations improve meaningful clinical outcomes beyond standard imaging and clinical assessment. Potential confounders such as clonal hematopoiesis and tumor heterogeneity may affect ctDNA accuracy and require careful consideration.
How this may change practice
If validated, ctDNA-guided treatment adaptation could transform metastatic bladder cancer management by enabling real-time, personalized therapy adjustments. Clinicians might use ctDNA status post-induction therapy to identify patients at high relapse risk who could benefit from intensified immunotherapy or early switch to alternative agents. Serial ctDNA monitoring could detect emerging resistance earlier than imaging, prompting timely treatment modifications and potentially improving progression-free survival.
Incorporating ctDNA into clinical workflows would require access to reliable, standardized assays and multidisciplinary collaboration for interpretation. It may also facilitate de-escalation strategies in patients with rapid ctDNA clearance, sparing them unnecessary toxicity. However, until robust prospective data confirm clinical benefit, ctDNA-guided treatment adaptation should remain investigational and ideally be performed within clinical trials or specialized centers.